The company's technology utilizes DNA methylation to detect different types of cancer including lung, liver, bladder, prostate, colorectal, breast, pancreatic, thyroid, gastric cancer, and leukemia from extracted DNA using a non-invasive blood test. Exact Sciences, USA Exact has developed Oncoguard Liver, a genetic-based treatment selection test. It is also building a multi-cancer early screening test, Cancerguard to detect over 14 cancers. Glycotest, USA Developer of a non-invasive blood test to provide information on the likelihood of hepatocellular carcinoma. It measures the amount of monosaccharide fucose that appears abnormally high on certain glycoproteins to indicate the likelihood of disease. 201 GRAIL, USA Developer of a multi-cancer early detection test kit, Galleri, designed to detect more than 50 types of cancer through non-invasive blood analysis. Galleri received FDA breakthrough device designation in 2019. 188 Helio Genomics, USA Developer of HelioLiver, a multi-analyte blood test that evaluates cell free DNA methylation patterns, serum protein markers, and demographic information for the detection of hepatocellular carcinoma.